Safety and efficacy of tivozanib–nivolumab combination in patients with metastatic kidney cancer
In this phase 1b/2 study the researchers looked at a [...]
Safety and efficacy of TiNivo in patients with metastatic kidney cancer
Tivozanib is a drug that blocks the blood supply to [...]
Cabozantinib after immunotherapy in advanced kidney cancer
This recent retrospective study included 84 patients with metastatic renal [...]
Safety and efficacy of nivolumab for non-clear cell kidney cancer
Nivolumab alone and in combination with ipilimumab is used for the treatment of [...]
Survival outcomes for patients on ipilimumab plus nivolumab combination therapy
Further results from the ongoing CheckMate 214 phase III study [...]
Combination of potential biomarkers may help predict response to immunotherapy in kidney cancer
Currently, it is difficult for clinicians to decide which patients [...]
Potential biomarker for response to nivolumab for kidney cancer
Nivolumab was the first immunotherapy to be approved for the [...]
Immune-related adverse events and clinical outcome in kidney cancer treated with nivolumab
In a paper published in Clinical Genitourinary Cancer the link [...]
ASCO 2020: Nivolumab plus ipilimumab combination for previously treated kidney cancer
Results from the phase II FRACTION-RCC clinical trial to assess [...]
ASCO 2020: Optimised treatment of advanced kidney cancer with nivolumab and ipilimumab
Two studies were presented during the 2020 American Society of [...]
